Literature DB >> 11705695

Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.

E S Arnér1, H Nakamura, T Sasada, J Yodoi, A Holmgren, G Spyrou.   

Abstract

Several studies have demonstrated a correlation between cellular toxicity of cis-diamminedichloroplatinum (II) (cisplatin, CDDP) and inhibited intracellular activity of the thioredoxin system, i.e., thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH. Conversely, increased cellular activity of the Trx system confers resistance to CDDP. In this study, we have analyzed the interaction of CDDP with Trx and TrxR in order to clarify the mechanism. The inhibition with time-dependent kinetics by CDDP of NADPH-reduced (but not oxidized) TrxR was irreversible, strongly suggesting covalent modification of the reduced selenocysteine-containing active site. Assuming second order kinetics, the rate constant of TrxR inhibition by CDDP was 21 +/- 3 M(-1) x s(-1). Transplatin was found to be an even more efficient inhibitor, with a second order rate constant of 84 +/- 22 M(-1) x s(-1), whereas carboplatin (up to 1 mM) gave no inhibition of the enzyme under the same conditions. Escherichia coli Trx or human or bacterial glutaredoxin (Grx) activities were in comparison only slightly or not at all inhibited by either CDDP, transplatin, or carboplatin. However, glutaredoxins were found to be inhibited by the purified glutathione adduct of cisplatin, bis-(glutathionato)platinum(II) (GS-Platinum complex, GS-Pt), with an IC50 = 350 microM in the standard beta-hydroxyethyl disulfide-coupled assay for human Grx. Also the mammalian Trx system was inhibited by GS-Pt with similar efficiency (IC(50) = 325 microM), whereas neither the E. coli Trx system nor glutathione reductase were inhibited. Formation of GS-Pt is a major route for cellular elimination of CDDP. The fact that GS-Pt inhibits the mammalian Trx as well as Grx systems shows that CDDP may exert effects at several stages of its metabolism, including after conjugation with GSH, which are intimately linked with the cellular disulfide/dithiol redox regulatory systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705695     DOI: 10.1016/s0891-5849(01)00698-0

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  40 in total

1.  The selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities.

Authors:  Qing Cheng; William E Antholine; Judith M Myers; Balaraman Kalyanaraman; Elias S J Arnér; Charles R Myers
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction.

Authors:  Robyn L Poerschke; Philip J Moos
Journal:  Biochem Pharmacol       Date:  2010-10-12       Impact factor: 5.858

3.  S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs.

Authors:  Christina L Grek; Danyelle M Townsend; Joachim D Uys; Yefim Manevich; Woodrow J Coker; Christopher J Pazoles; Kenneth D Tew
Journal:  Cancer Res       Date:  2012-03-08       Impact factor: 12.701

4.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

5.  The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin.

Authors:  Yongke Lu; Arthur Cederbaum
Journal:  Free Radic Biol Med       Date:  2007-07-06       Impact factor: 7.376

Review 6.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

7.  The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.

Authors:  Jennifer D Tibodeau; Linda M Benson; Crescent R Isham; Whyte G Owen; Keith C Bible
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

8.  Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry.

Authors:  Joanna Will; William S Sheldrick; Dirk Wolters
Journal:  J Biol Inorg Chem       Date:  2007-12-22       Impact factor: 3.358

9.  N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS).

Authors:  Medhi Wangpaichitr; Chunjing Wu; Min You; Johnathan C Maher; Vy Dinh; Lynn G Feun; Niramol Savaraj
Journal:  Cancers (Basel)       Date:  2009       Impact factor: 6.639

10.  Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping.

Authors:  Judith M Myers; Qing Cheng; William E Antholine; Balaraman Kalyanaraman; Aleksandra Filipovska; Elias S J Arnér; Charles R Myers
Journal:  Free Radic Biol Med       Date:  2013-02-26       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.